Ovarian cancer is the sixth most common malignancy among women in developed countries and the fifth leading cause of cancer-related death, representing a complex disease associated with poor survival rates.24 The combination chemotherapy of Paclitaxel (PTX) and Carboplatin (CARB) is considered the first-line treatment regimen for ovarian cancer.25 Both agents play distinct roles in inhibiting the growth of ovarian cancer through different mechanisms,26 and they are known to exert a synergistic anti-tumor effect by activating separate apoptotic signaling pathways, thereby potentially reducing drug resistance.25 The gonadotoxic effects of platinum-based chemotherapeutic agents have been demonstrated in numerous studies, both histopathologically and in terms of follicular development.27-29 In the present study, CARB administration led to significant histopathological damage in ovarian tissue, including follicular degeneration, prominent stromal edema, congestion, hemorrhage, inflammation, and fibrosis, particularly in the medullary region

DOI: 10.1016/s0736-5748(00)00013-7 77
Hair loss can be a symptom of underlying health conditions
Most consumer testing of copper peptide creams measures surface hydration, not dermal delivery
Muradov for: Chronic fatigue, burnout & low energy Digestive disorders, IBS, bloating, food sensitivities & microbiome imbalances Thyroid disorders & adrenal fatigue (hypocortisolism) Hormone imbalances (PMS, PCOS, menopause, testosterone) Autoimmune conditions Neurological concerns such as Multiple Sclerosis Evidence-based IV nutrient therapy & complex IV protocols Training & Expertise Dr